|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Devesa SS, Bray F, Vizcaino AP and Parkin
DM: International lung cancer trends by histologic type:
male:female differences diminishing and adenocarcinoma rates
rising. Int J Cancer. 117:294–299. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morgensztern D, Ng SH, Gao F and Govindan
R: Trends in stage distribution for patients with non-small cell
lung cancer: A National Cancer Database survey. J Thorac Oncol.
5:29–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma D, Wang J, Hao X, Wang Y, Hu X, Xing P
and Li J: Gemcitabine combined with cisplatin as adjuvant
chemotherapy for non-small cell lung cancer: A retrospective
analysis. Thorac Cancer. 8:482–488. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jia Y, Zhou D, Jia Q, Ying Y and Chen S:
Synergistic and attenuated effect of HSS in combination treatment
with docetaxel plus cisplatin in human non-small-cell lung SPC-A-1
tumor xenograft. Biomed Pharmacother. 79:27–34. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Müller A, Zang C, Chumduri C, Dörken B,
Daniel PT and Scholz CW: Concurrent inhibition of PI3K and
mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis
by down-regulation of Mcl-1 in mantle cell lymphoma. Int J Cancer.
133:1813–1824. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sasore T, Reynolds AL and Kennedy BN:
Targeting the PI3K/Akt/mTOR pathway in ocular neovascularization.
Adv Exp Med Biol. 801:805–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li H, Zhang B, Liu Y and Yin C: EBP50
inhibits the migration and invasion of human breast cancer cells
via LIMK/cofilin and the PI3K/Akt/mTOR/MMP signaling pathway. Med
Oncol. 31:1622014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma J, Sawai H, Matsuo Y, Ochi N, Yasuda A,
Takahashi H, Wakasugi T, Funahashi H, Sato M and Takeyama H: IGF-1
mediates PTEN suppression and enhances cell invasion and
proliferation via activation of the IGF-1/PI3K/Akt signaling
pathway in pancreatic cancer cells. J Surg Res. 160:90–101. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Burris HA III: Overcoming acquired
resistance to anticancer therapy: Focus on the PI3K/AKT/mTOR
pathway. Cancer Chemother Pharmacol. 71:829–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu JL, Wang ZW, Hu LM, Yin ZQ, Huang MD,
Hu ZB, Shen HB and Shu YQ: Genetic variants in the
PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy
response of advanced non-small cell lung cancers in a Chinese
population. Asian Pac J Cancer Prev. 13:2157–2162. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reungwetwattana T, Weroha SJ and Molina
JR: Oncogenic pathways, molecularly targeted therapies, and
highlighted clinical trials in non-small-cell lung cancer (NSCLC).
Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tsodikov OV, Enzlin JH, Schärer OD and
Ellenberger T: Crystal structure and DNA binding functions of
ERCC1, a subunit of the DNA structure-specific endonuclease
XPF-ERCC1. Proc Natl Acad Sci USA. 102:11236–11241. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai Y, Yan X, Zhang G, Zhao W and Jiao S:
The predictive value of ERCC1 and p53 for the effect of
panobinostat and cisplatin combination treatment in NSCLC.
Oncotarget. 6:18997–19005. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee HW, Choi YW, Han JH, Kim JH, Jung JH,
Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, et al: Expression of
excision repair cross-complementation group 1 protein predicts poor
outcome in advanced non-small cell lung cancer patients treated
with platinum-based doublet chemotherapy. Lung Cancer. 65:377–382.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Palomba G, Atzori F, Budroni M, Ombra M,
Cossu A, Sini M, Pusceddu V, Massidda B, Frau B, Notari F, et al:
ERCC1 polymorphisms as prognostic markers in T4 breast cancer
patients treated with platinum-based chemotherapy. J Transl Med.
12:2722014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yun J, Kim KM, Kim ST, Kim JH, Kim JA,
Kong JH, Lee SH, Won YW, Sun JM, Lee J, et al: Predictive value of
the ERCC1 expression for treatment response and survival in
advanced gastric cancer patients receiving cisplatin-based
first-line chemotherapy. Cancer Res Treat. 42:101–106. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang S, Pan H, Liu D, Mao N, Zuo C, Li L,
Xie T, Huang D, Huang Y, Pan Q, et al: Excision repair cross
complementation group 1 is a chemotherapy-tolerating gene in
cisplatin-based treatment for non-small cell lung cancer. Int J
Oncol. 46:809–817. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Song W and Ma H: The expression of ERCC1
and BRCA1 predicts prognosis of platinum-based chemotherapy in
urothelial cancer. Onco Targets Ther. 9:3465–3471. 2016.PubMed/NCBI
|
|
20
|
Usanova S, Piée-Staffa A, Sied U, Thomale
J, Schneider A, Kaina B and Köberle B: Cisplatin sensitivity of
testis tumour cells is due to deficiency in interstrand-crosslink
repair and low ERCC1-XPF expression. Mol Cancer. 9:2482010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chang IY, Kim MH, Kim HB, Lee DY, Kim SH,
Kim HY and You HJ: Small interfering RNA-induced suppression of
ERCC1 enhances sensitivity of human cancer cells to cisplatin.
Biochem Biophys Res Commun. 327:225–233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qin X, Yao W, Li W, Feng X, Huo X, Yang S,
Zhao H and Gu X: ERCC1 and BRCA1 mRNA expressions are associated
with clinical outcome of non-small cell lung cancer treated with
platinum-based chemotherapy. Tumour Biol. 35:4697–4704. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herrera VA, Zeindl-Eberhart E, Jung A,
Huber RM and Bergner A: The dual PI3K/mTOR inhibitor BEZ235 is
effective in lung cancer cell lines. Anticancer Res. 31:849–854.
2011.PubMed/NCBI
|
|
24
|
Chen L, Jin T, Zhu K, Piao Y, Quan T, Quan
C and Lin Z: PI3K/mTOR dual inhibitor BEZ235 and histone
deacetylase inhibitor Trichostatin A synergistically exert
anti-tumor activity in breast cancer. Oncotarget. 8:11937–11949.
2017.PubMed/NCBI
|
|
25
|
Xie G, Wang Z, Chen Y, Zhang S, Feng L,
Meng F and Yu Z: Dual blocking of PI3K and mTOR signaling by
NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and
enhances therapeutic response. Cancer Lett. 388:12–20. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qu Y, Wu X, Yin Y, Yang Y, Ma D and Li H:
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in
combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant
NSCLC xenograft models. J Exp Clin Cancer Res. 33:522014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Piao J, Chen L, Quan T, Li L, Quan C, Piao
Y, Jin T and Lin Z: Superior efficacy of co-treatment with the dual
PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor
Trichostatin A against NSCLC. Oncotarget. 7:60169–60180. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Maira SM, Stauffer F, Brueggen J, Furet P,
Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker
K, et al: Identification and characterization of NVP-BEZ235, a new
orally available dual phosphatidylinositol 3-kinase/mammalian
target of rapamycin inhibitor with potent in vivo antitumor
activity. Mol Cancer Ther. 7:1851–1863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Torki S, Soltani A, Shirzad H, Esmaeil N
and Ghatrehsamani M: Synergistic antitumor effect of NVP-BEZ235 and
CAPE on MDA-MB-231 breast cancer cells. Biomed Pharmacother.
92:39–45. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Eastman A: The formation, isolation and
characterization of DNA adducts produced by anticancer platinum
complexes. Pharmacol Ther. 34:155–166. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Torii Y, Kato R, Minami Y, Hasegawa K,
Fujii T and Udagawa Y: ERCC1 expression and chemosensitivity in
uterine cervical adenocarcinoma cells. Anticancer Res. 34:107–115.
2014.PubMed/NCBI
|
|
33
|
Li Q, Tsang B, Bostick-Bruton F and Reed
E: Modulation of excision repair cross complementation group 1
(ERCC-1) mRNA expression by pharmacological agents in human ovarian
carcinoma cells. Biochem Pharmacol. 57:347–353. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fong MY and Kakar SS: The role of cancer
stem cells and the side population in epithelial ovarian cancer.
Histol Histopathol. 25:113–120. 2010.PubMed/NCBI
|
|
35
|
Yang H and Dou QP: Targeting apoptosis
pathway with natural terpenoids: Implications for treatment of
breast and prostate cancer. Curr Drug Targets. 11:733–744. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de Souza PM and Lindsay MA: Apoptosis as a
therapeutic target for the treatment of lung disease. Curr Opin
Pharmacol. 5:232–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li QQ, Lee RX, Liang H, Zhong Y and Reed
E: Enhancement of cisplatin-induced apoptosis by β-elemene in
resistant human ovarian cancer cells. Med Oncol. 30:4242013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sun A, Chia JS, Chiang CP, Hsuen SP, Du
JL, Wu CW and Wang WB: The chinese herbal medicine Tien-Hsien
liquid inhibits cell growth and induces apoptosis in a wide variety
of human cancer cells. J Altern Complement Med. 11:245–256. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Neuzil J, Tomasetti M, Mellick AS, Alleva
R, Salvatore BA, Birringer M and Fariss MW: Vitamin E analogues: A
new class of inducers of apoptosis with selective anti-cancer
effects. Curr Cancer Drug Targets. 4:355–372. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang Z, Schumaker LM, Egorin MJ, Zuhowski
EG, Guo Z and Cullen KJ: Cisplatin preferentially binds
mitochondrial DNA and voltage-dependent anion channel protein in
the mitochondrial membrane of head and neck squamous cell
carcinoma: Possible role in apoptosis. Clin Cancer Res.
12:5817–5825. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yan M, Ni J, Song D, Ding M and Huang J:
Activation of unfolded protein response protects osteosarcoma cells
from cisplatin-induced apoptosis through NF-κB pathway. Int J Clin
Exp Pathol. 8:10204–10215. 2015.PubMed/NCBI
|
|
43
|
Wolf BB, Schuler M, Echeverri F and Green
DR: Caspase-3 is the primary activator of apoptotic DNA
fragmentation via DNA fragmentation factor-45/inhibitor of
caspase-activated DNase inactivation. J Biol Chem. 274:30651–30656.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yu Y, Yu X, Ma J, Tong Y and Yao J:
Effects of NVP-BEZ235 on the proliferation, migration, apoptosis
and autophagy in HT-29 human colorectal adenocarcinoma cells. Int J
Oncol. 49:285–293. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bhende PM, Park SI, Lim MS, Dittmer DP and
Damania B: The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious
against follicular lymphoma. Leukemia. 24:1781–1784. 2010.
View Article : Google Scholar : PubMed/NCBI
|
